← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
omeprazole, combinations
A02BC51
Forms & Strengths
- Omeprazole 10 mg / Sodium bicarbonate 1100 mg capsules/powder for suspension
- Omeprazole 20 mg / Sodium bicarbonate 1100 mg capsules/powder for suspension
- Omeprazole 40 mg / Sodium bicarbonate 1100 mg capsules/powder for suspension
Adult Dosing
- Duodenal ulcer: 20 mg to 40 mg once daily for 4 to 8 weeks
- Gastric ulcer: 40 mg once daily for 4 to 8 weeks
- Gastroesophageal Reflux Disease (GERD): 20 mg once daily for up to 4 to 8 weeks
- Zollinger-Ellison syndrome: 60 mg once daily, adjusted up to 120 mg three times daily
Pediatric Dosing
- Safety and efficacy of omeprazole/sodium bicarbonate combinations have not been established in pediatric patients under 18 years of age
Indications
- Short-term treatment of active duodenal ulcer
- Short-term treatment of active benign gastric ulcer
- Treatment of symptomatic GERD and erosive esophagitis
- Pathological hypersecretory conditions including Zollinger-Ellison syndrome
Mechanism of Action
- Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell
- Sodium bicarbonate acts as an antacid to rapidly neutralize gastric acid, protecting omeprazole from acid degradation in the stomach
Contraindications
- Known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation
- Concomitant use with rilpivirine-containing products
Adverse Reactions
- Headache
- Abdominal pain
- Nausea
- Diarrhea
- Vomiting
- Flatulence
- Hyponatremia and hypomagnesemia (with long-term use)
- Increased risk of Clostridioides difficile-associated diarrhea
Drug Interactions
- Drugs dependent on gastric pH for absorption (e.g., ketoconazole, iron salts, dasatinib, erlotinib): absorption may be significantly reduced
- CYP2C19 inhibitors (e.g., esomeprazole, fluvoxamine) or inducers (e.g., rifampin, St. John's wort) may alter omeprazole clearance
- Warfarin: increased INR and prothrombin time monitoring required
- Methotrexate: concomitant use may elevate and prolong serum levels of methotrexate and/or its metabolite
- Clopidogrel: omeprazole decreases the antiplatelet effect of clopidogrel via CYP2C19 inhibition
Curated Content: Needs Vetting Before Put to Clinical Use